25
Participants
Start Date
June 30, 2012
Primary Completion Date
August 31, 2016
Study Completion Date
June 23, 2017
Cabazitaxel
25 mg/m2 or 20 mg/m2, IV, once every 21 days
Mitoxantrone
4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
Prednisone
5 mg PO BID
Pegfilgrastim
6 mg, SC, once every 21 days
Vanderbilt-Ingram Cancer Center, Nashville
Mayo Clinic, Scottsdale
UCSF Comprehensive Cancer Center, San Francisco
Collaborators (1)
Sanofi
INDUSTRY
Rahul Aggarwal
OTHER